Earnings Call Summary | Exscientia(EXAI.US) Q4 2023 Earnings Conference
Earnings Call Summary | Exscientia(EXAI.US) Q4 2023 Earnings Conference
The following is a summary of the Exscientia Plc (EXAI) Q4 2023 Earnings Call Transcript:
以下是Exscientia Plc（EXAI）2023年第四季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Exscientia concluded the year with a bank balance of $463 million in cash and fixed-term deposits.
An operational cash burn of $150 million for the previous year was reported.
A reduced operational cash burn is expected for 2024 compared to 2023.
With the current financial runway, the company's funds are projected to last well into 2026, allowing for further platform development and pipeline progression.
Exscientia在今年年底的銀行存款餘額爲4.63億美元的現金和定期存款。
據報道，上一年的運營現金消耗爲1.5億美元。
與2023年相比，預計2024年的運營現金消耗將減少。
在目前的財務狀況下，該公司的資金預計將持續到2026年，從而允許進一步的平台開發和管道進展。
Business Progress:
業務進展：
The company made strides in expanding its technological capabilities, including launching an automation suite near Oxford.
Ongoing internal pipeline initiatives centered on high-value oncology targets, with programs such as GTA-EXS-617 and EXS74539 advancing.
Expanded collaborations with Sanofi and Merck KGaA, and focus on CDK7 inhibitor and LSD1 inhibitor for possible cancer treatments.
From an investment in automation, a significant financial impact is anticipated within a few years due to cost savings.
Exscientia marked its first milestone within its Sanofi collaboration in late 2023 and expects a rise in milestones in the next 18 to 36 months.
The CDK7 program is progressing through its monotherapy dose escalation phase, with results expected in 2024.
Plans to file each IND for the LSD1 inhibitor in early Q3-2024, with the first patient expected to be dosed by year's end.
Expressed an interest in further partnerships and exploring alliances with tech companies to boost their precise data-focused approach.
該公司在擴大其技術能力方面取得了長足的進步，包括在牛津附近推出自動化套件。
正在進行的內部研發計劃以高價值腫瘤學靶標爲中心，GTA-EXS-617 和 EXS74539 等項目正在推進。
擴大了與賽諾菲和默沙東KGaA的合作，重點開發用於可能的癌症治療的CDK7抑制劑和LSD1抑制劑。
通過對自動化的投資，由於成本的節約，預計將在幾年內產生重大的財務影響。
Exscientia在2023年底標誌着其與賽諾菲合作中的第一個里程碑，並預計在未來18至36個月內，里程碑將增加。
CDK7計劃正在進入單一療法劑量遞增階段，預計將在2024年取得成果。
計劃在 Q3-2024 早期提交每個 LSD1 抑制劑的臨床試驗報告，預計第一位患者將在年底前服藥。
表示有興趣與科技公司建立進一步的合作伙伴關係並探索結盟關係，以推動他們以數據爲中心的精確方法。
More details: Exscientia IR
更多詳情： Exscientia IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。